Hikari Power Ltd Sells 22,090 Shares of Amgen Inc. $AMGN

Hikari Power Ltd lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 71.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,900 shares of the medical research company’s stock after selling 22,090 shares during the period. Amgen makes up about 0.4% of Hikari Power Ltd’s holdings, making the stock its 19th biggest position. Hikari Power Ltd’s holdings in Amgen were worth $3,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Anfield Capital Management LLC grew its position in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares in the last quarter. Dogwood Wealth Management LLC raised its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Tower View Wealth Management LLC raised its position in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC raised its position in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Amgen during the fourth quarter valued at $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent analyst reports. Barclays boosted their target price on Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a research report on Friday. Cantor Fitzgerald lifted their price target on Amgen from $350.00 to $400.00 and gave the company a “neutral” rating in a research report on Tuesday. Truist Financial lifted their price target on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Scotiabank boosted their price objective on Amgen from $385.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Wells Fargo & Company raised their target price on shares of Amgen from $390.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $375.93.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus
• Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study
• Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock
• Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations.
• Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders.

Amgen Trading Up 1.4%

NASDAQ AMGN opened at $425.28 on Wednesday. The stock’s 50-day simple moving average is $373.66 and its two-hundred day simple moving average is $360.06. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $427.39. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The company has a market capitalization of $229.92 billion, a price-to-earnings ratio of 26.43, a PEG ratio of 3.86 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the previous year, the company posted $6.02 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. Amgen’s payout ratio is presently 62.65%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.